Acne in ethnic skin: Special considerations for therapy

Dermatologic Therapy

Volumn 17, Issue 2, 2004, Pages 184-195

  Callender, Valerie D ^a,b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Callender Skin and Laser Center   (United States)

Author keywords

Acne vulgaris; Ethnic skin; Hydroquinone; Keloids; Postinflammatory hyperpigmentation; Retinoids

Indexed keywords

ADAPALENE; ALUSTRA; AMBI; AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; BLACK OPAL FADE; CEPHALOSPORIN DERIVATIVE; CLARIPEL; CLINDAMYCIN; CORTICOSTEROID; DOXYCYCLINE; ELDOPAQUE FORTE; ELDOQUIN FORTE; EPIQUIN MICRO; ERYTHROMYCIN; ESOTERICA; ETHINYLESTRADIOL; GLYQUIN; GLYQUIN XM; HYDROQUINONE; IMMUNOMODULATING AGENT; ISOTRETINOIN; LUSTRA; LUSTRA AF; METAHEXAMIDE; MINOCYCLINE; NEOSTRATA HQ; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PIMECROLIMUS; PORCELANA; PREDNISONE; RETINOIC ACID; RETINOID; SALICYLIC ACID; SOLAQUIN FORTE; SPIRONOLACTONE; SULFACETAMIDE; SULFONAMIDE; TACROLIMUS; TAZAROTENE; TETRACYCLINE; TRI LUMA; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANTEX;

ACNE VULGARIS; DEPIGMENTATION; DRY SKIN; HALO EFFECT; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; KELOID; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN COLOR; SKIN IRRITATION; TITRIMETRY; TREATMENT INDICATION; TREATMENT PLANNING;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; GLYCOLATES; HUMANS; HYALURONIC ACID; HYDROQUINONES; HYPERPIGMENTATION; KERATOLYTIC AGENTS; RETINOIDS;

EID: 2442711418     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04019.x     Document Type: Review

References (70)

1. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 1998: 39: S34-S37.
2. American Academy of Dermatology. The social impact of acne. [WWW document.] URL http://www.skincarephysicians.com/acnenet/socimpct.html (Accessed February 2003.)
3. Barankin B, DeKoven J. Psychosocial effect of common skin diseases. Can Fam Physician 2002: 48: 712-716.
4. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999: 140: 672-676.
5. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999: 140: 273-282.
6. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med 2000: 9: 179-187.
7. US Census Bureau. Population Projections Program, Washington D.C. Table NP-T5-B (middle series projections). January 13, 2000.
8. Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis 1983: 32: 390.
9. Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol 2002: 46 (Suppl.): S98-S106.
10. Centers for Disease Control and National Center for Health Statistics. Current Estimates From the National Health Interview Survey. 1996. Series 10, No. 200. Table 59.
11. Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in healthcare. Summary. Washington, DC: National Academies of Sciences, 2003.
12. Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995: 32 (Suppl.): S15-S25.
13. Warrier AG, Kligman AM, Harper RA, Bowman J, Wickett RR. A comparison of black and white skin using noninvasive methods. Soc Comet Chem 1996: 47: 229-240.
14. Pochi PE, Strauss JS. Sebaceous gland activity in black skin. Dermatol Clin 1988: 6: 349.
15. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002: 46 (Suppl.): S41-S62.
16. Perez A, Sanchez JL. Treatment of acne vulgaris in skin of color. Cosmetic Derm 2003: 16: 23-28.
17. Wilkins JW, Voorhees JJ. Prevalence of nodulocystic acne in white and Negro males. Arch Dermatol 1970: 102: 631-634.
18. Kelly AP, Sampson DD. Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin. J Nat Med Assoc 1987: 79: 1266-1270.
19. National Institutes of Health. Health disparities in arthritis and musculoskeletal and skin diseases-the dermatology session. [WWW document.] URL http://www.niams.nih.gov/ ne/reports/sci_wrk/2000/hdconf_final.htm (Accessed May 15, 2003.)
20. Halder RM, Holmes YC, Bridgeman-Shah S, Kligman AM. A clinicohistopathologic study of acne vulgaris in black females. [Abstract.] J Invest Dermatol 1996: 106: 495A.
21. Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol 2003: 48 (Suppl.): S143-S148.
22. Andersen KE, Maibach H. Black and white human skin differences. J Am Acad Dermatol 1979: 1: 276-282.
23. Grimes PR, Stockton T. Pigmentary disorders in blacks. Dermatol Clin 1988: 6: 271-281.
24. Taylor SC. Cosmetic problems in skin of color. Skin Pharmacol Appl Skin Physiol 1999: 12: 139-143.
25. Kelly AP. Keloids: pathogenesis and treatment. Cosmetic Derm 2003:16:29-32.
26. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002: 46 (Suppl.): S63-S97.
27. Kligman AM, Mills OH. Acne cosmetica. Arch Dermatol 1972: 106: 843-850.
28. Grimes P. Skin and hair cosmetic issues in women of color. Dermatol Clin 2000: 18: 659-665.
29. Plewig G, Fulton JE, Kligman AM. Pomade acne. Arch Derm 1970: 580-584.
30. Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol 1998: 39 (Suppl.): S98-S103.
31. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999: 63: 349-354.
32. Wolf JE. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther 2002: 19: 109-118.
33. Daly TJ, Weston WL. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol 1986: 15: 900-902.
34. Abergel RP, Meeker CA, Oikarinen H, Oikarinen AI, Uitto J. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch Dermatol 1985: 12: 632-635.
35. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis 2001: 68: 48-54.
36. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993: 328: 1438-1443.
37. Grimes PE, Callender VD. Tazarotene cream 0.1% in the treatment of facial post-inflammatory hyperpigmentation associated with acne vulgaris: a two-center, double-blind, randomized, vehicle-controlled study. Poster presented at the 61st Annual Meeting of the American Academy Dermatology, San Francisco, CA, March 21-26, 2003.
38. Grimes PE. Using tazarotene to treat acne in patients with skin types V or VI. Poster presented at the 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, February 22-27, 2002.
39. Czernielewski J, Poncet M, Mizzi F. Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris. Cutis 2002: 70: 243-248.
40. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis 2001: 67 (Suppl.): 21-24.
41. Mills OH, Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol, 1986: 25: 664-667.
42. Webster G. Combination azelaic acid therapy for acne vulgaris. J Am Acad Dermatol 2000: 43: S47-S50.
43. Nguyen QH, Bui TP. Azelaic acid. pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol 1995: 34: 75-84.
44. Jimbow K, Obata H, Pathak M, Fitzpatrick T. Mechanisms of depigmentation by hydroquinone. J Invest Dermatol 1997: 62: 436-449.
45. Callender VD. Hyperpigmentation in an African American patient with acne. Cosm Derm 2003: 16 (Suppl.): 1-3.
46. Findlay GH, Morrison JG, Simson IW. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. Br J Dermatol 1975: 93: 613-622.
47. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001: 2: 213-217.
48. Barrientos N, Ortiz-Frutos J, Gomez E, Iglesias L. Allergic contact dermatitis from a bleaching cream. Am J Contact Dermat 2001: 12: 33-34.
49. Nakagawa K, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermat 1995: 32: 9-13.
50. Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermat 1998: 39: 86.
51. Webster GF. Inflammatory acne. Int J Dermatol 1990: 29: 313-317.
52. Webster GF, Leyden JJ, McGinley KJ, McArthur WP. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by sub-minimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother 1982: 21: 770-772.
53. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998: 196: 140-147.
54. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002: 46: 505-509.
55. Hanson N, Leachman S. Safety issues in isotretinoin therapy. Semin Cutan Med Surg 2001: 20: 166-183.
56. Shaw JC. Understanding the role of hormones in acne. Skin Aging 2002; September: 64-69.
57. Harper JC. Hormones and acne. Skin Aging 2002: September: 72-75.
58. Wang CM, Huang CL, Hu CT, Chan HL. The effect of glycolic acid on the treatment of acne in Asian skin. Dermatol Surg 1997: 23: 23-29.
59. Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg 1997: 23: 171-174.
60. Al-Waiz MM, Al-Sharqi AI. Medium-depth chemical peels in the treatment of acne scars in dark-skinned individuals. Dermatol Surg 2002: 28: 383-387.
61. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999: 25: 18-22.
62. Callender VD. Cosmetic surgery in skin of color. Cosm Derm: 2203: 53-56.
63. Rajan P, Grimes PE. Skin barrier changes induced by aluminum oxide and sodium chloride microdermabrasion. Dermatol Surg 2002: 28: 390-393.
64. Greeley A. Cosmetic laser surgery. FDA Consumer. [WWW document.] URL http://www.fda.gov/fdac/features/2000/ 300_laser.html (Accessed August 2000.)
65. Lloyd JR, Mirkov M. Selective photothermolysis of the sebaceous glands for acne treatment. Lasers Surg Med 2002: 31: 115-120.
66. Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002: 31: 106-114.
67. Ruiz-Esparza J, Gomez JB. Nonablative radiofrequency for active acne vulgaris: the use of deep dermal heat in the treatment of moderate to severe active acne vulgaris (thermotherapy). A report of 22 patients. Dermatol Surg 2003: 29: 333-339.
68. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol 2000: 142: 973-978.
69. Kawada A, Aragane Y, Kameyama H, Sangen Y, Tezuka T. Acne phototherapy with a high-intensity, enhanced, narrow-band, blue light source: an open study and in vitro investigation. J Dermatol Sci 2002: 30: 129-135.
70. Jordan RE, Cummins CL, Burls AJ, Seukeran DC. Laser resurfacing for facial acne scars. Cochrane Database Syst Rev 2001: 2: CD001866.